Original Research

Cost of Diagnosing Psoriasis and Rosacea for Dermatologists Versus Primary Care Physicians

From the Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina. Dr. Feldman also is from the Departments of Pathology and Public Health Sciences.

The Center for Dermatology Research is supported by an unrestricted educational grant from Galderma Laboratories, LP. The authors report no conflict of interest.

Correspondence: Dane Hill, MD, Department of Dermatology, Wake Forest School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157-1071 (danehill25@gmail.com).


 

References

Comment

For the management of common skin disorders such as psoriasis and rosacea, there is little cost difference in seeing a dermatologist versus a PCP. Through extensive training and repeated exposure to many skin diseases, dermatologists are expected to be more comfortable in diagnosing and managing psoriasis and rosacea. Compared to PCPs, dermatologists have demonstrated increased diagnostic accuracy and efficiency when examining pigmented lesions and other dermatologic diseases in several studies.3-6 Although the current study shows that diagnosis-related costs for psoriasis and rosacea are essentially equal between dermatologists and PCPs, it actually may be less expensive for patients to see a dermatologist, as unnecessary tests, biopsies, or medications are more likely to be ordered/prescribed when there is less clinical diagnostic certainty.7,8 Additionally, seeing a PCP for diagnosis of a skin disease may be inefficient if subsequent referral to a dermatologist is needed, a common scenario that occurs when patients see a PCP for skin conditions.9

Our study had limitations, which is typical of a study using a claims database. We used ICD-9 codes recorded in patients’ medical claims to determine diagnosis of psoriasis and rosacea; therefore, our study and data are subject to coding errors. We could not assess the severity of disease, only the presence of disease. Further confirmation of diagnosis could have been made through searching for a second ICD-9 code in the patient’s history. Our data also are from a limited time period and may not represent costs from other time periods.

Conclusion

Given the lack of cost difference between both specialties, we conclude that ACOs should consider encouraging patients to seek care for dermatologic diseases by dermatologists who generally are more accurate and efficient skin diagnosticians, particularly if there is a shortage of PCPs within the ACO network.

Pages

Recommended Reading

Fixed combination topical shows promise for psoriasis
Psoriasis Collection
Bone fractures more likely to occur in psoriasis, PsA patients
Psoriasis Collection
Severe Henoch-Schönlein Purpura Complicating Infliximab Therapy for Ulcerative Colitis
Psoriasis Collection
FDA opens abbreviated approval pathway for interchangeable biosimilars
Psoriasis Collection
MTX side effects limit patient use
Psoriasis Collection
VIDEO: Interchangeability of biosimilars and parent compounds raise potential efficacy issues
Psoriasis Collection
VIDEO: Adding methotrexate to a biologic may help achieve treatment goal
Psoriasis Collection
The Role of Biologic Therapy for Psoriasis in Cardiovascular Risk Reduction
Psoriasis Collection
VIDEO: Pediatric psoriasis patients prepare for biologics
Psoriasis Collection
New Biologics in Psoriasis: An Update on IL-23 and IL-17 Inhibitors
Psoriasis Collection

Related Articles